These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 17391068)

  • 1. Primum non nocere: adverse drug events must be taken seriously.
    Gurwitz D; McLeod HL
    Pharmacogenomics; 2007 Apr; 8(4):311-4. PubMed ID: 17391068
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges.
    Issa AM
    Pharmacogenomics; 2003 Sep; 4(5):647-55. PubMed ID: 12943471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics and reducing the frequency of adverse drug events.
    O'Kane DJ; Weinshilboum RM; Moyer TP
    Pharmacogenomics; 2003 Jan; 4(1):1-4. PubMed ID: 12517278
    [No Abstract]   [Full Text] [Related]  

  • 4. Improving the reporting of adverse drug reactions in the hospital setting.
    Pushkin R; Frassetto L; Tsourounis C; Segal ES; Kim S
    Postgrad Med; 2010 Nov; 122(6):154-64. PubMed ID: 21084792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Invited commentary--prescription drug label adverse events: a call for prioritization: comment on "A quantitative analysis of adverse events and 'overwarning' in drug labeling".
    Cheng C; Guglielmo BJ
    Arch Intern Med; 2011 May; 171(10):946-7. PubMed ID: 21606102
    [No Abstract]   [Full Text] [Related]  

  • 6. Temporal relationship between multiple drugs and multiple events in patient reports on adverse drug reactions: findings in a pilot study in Japan.
    Kubota K; Okazaki M; Dobashi A; Yamamoto M; Hashiguchi M; Horie A; Inagaki A; Kikuchi T; Mochizuki M
    Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1134-7. PubMed ID: 24092565
    [No Abstract]   [Full Text] [Related]  

  • 7. A quantitative analysis of adverse events and "overwarning" in drug labeling.
    Duke J; Friedlin J; Ryan P
    Arch Intern Med; 2011 May; 171(10):944-6. PubMed ID: 21606101
    [No Abstract]   [Full Text] [Related]  

  • 8. Product-related adverse events in hemodialysis patients: improving recognition and response.
    Patel PR; Kallen AJ; Budnitz DS
    Am J Kidney Dis; 2010 May; 55(5):972; author reply 973. PubMed ID: 20438988
    [No Abstract]   [Full Text] [Related]  

  • 9. Primun non nocere, polypharmacy and pharmacogenetics.
    Isidoro-García M; Sánchez-Martín A; García-Berrocal B; Román-Curto C
    Pharmacogenomics; 2015 Nov; 16(17):1903-5. PubMed ID: 26554320
    [No Abstract]   [Full Text] [Related]  

  • 10. Update: adverse events following civilian smallpox vaccination--United States, 2003.
    Can Commun Dis Rep; 2003 Nov; 29(22):194-6. PubMed ID: 14650096
    [No Abstract]   [Full Text] [Related]  

  • 11. Experts call for active surveillance of drug safety.
    Wadman M
    Nature; 2007 Mar; 446(7134):358-9. PubMed ID: 17377551
    [No Abstract]   [Full Text] [Related]  

  • 12. Adverse effect reporting: pharmaceutical companies can't be trusted.
    Prescrire Int; 2015 Nov; 24(165):256. PubMed ID: 26688890
    [No Abstract]   [Full Text] [Related]  

  • 13. Primum non nocere.
    Gifford RW
    JAMA; 1977 Aug; 238(7):589-90. PubMed ID: 577959
    [No Abstract]   [Full Text] [Related]  

  • 14. ASHP guidelines on adverse drug reaction monitoring and reporting. American Society of Hospital Pharmacy.
    Am J Health Syst Pharm; 1995 Feb; 52(4):417-9. PubMed ID: 7757870
    [No Abstract]   [Full Text] [Related]  

  • 15. Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents.
    Meletiadis J; Chanock S; Walsh TJ
    Pharmacogenomics; 2008 May; 9(5):561-84. PubMed ID: 18466103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postmarketing modifications in the safety labeling of the new antiepileptics.
    Buck ML; Gurka MJ; Goodkin HP
    Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
    [No Abstract]   [Full Text] [Related]  

  • 17. Role of US poison centers in adverse drug reactions monitoring.
    Chyka PA
    Vet Hum Toxicol; 1999 Dec; 41(6):400-2. PubMed ID: 10592954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Special Section on Pharmacogenomics: recent advances and future directions.
    Mushiroda T; Giacomini KM; Kubo M
    J Hum Genet; 2013 Jun; 58(6):305. PubMed ID: 23797326
    [No Abstract]   [Full Text] [Related]  

  • 19. Can pharmacogenetics help rescue drugs withdrawn from the market?
    Shah RR
    Pharmacogenomics; 2006 Sep; 7(6):889-908. PubMed ID: 16981848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smallpox Vaccine Adverse Events Monitoring and Response System for the first stage of the smallpox vaccination program.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2003 Feb; 52(5):88-9, 99. PubMed ID: 12588007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.